- -
- 100%
- +
439
Hull JH, Garrod R, Но ТВ, et al. Increased augmentation index in patients with cystic fibrosis. Eur Respir J 2009; 34: 1322-8.
440
Hull JH, Garrod R, Но ТВ, et al. Dynamic vascular changes following intravenous antibiotics in patients with cystic fibrosis. J Cyst Fibros 2013; 12: 125-9.
441
A-Rahman AK, Spencer D. Totally implantable vascular access devices for cystic fibrosis. Cochrane Database Syst Rev 2012; 5:CD004111.
442
Batacchi S, Zagli G, Braccini G, et al. Totally implantable vascular access devices in adult patients for cystic fibrosis management. Am J Respir Crit Care Med 2011; 183:133-4.
443
Dal Molin A, Di Massimo DS, Braggion C, et al. Totally implantable central venous access ports in patients with cystic fibrosis: a multicenter prospective cohort study. J Vase Access 2012; 13: 290-5.
444
Garwood S, Flume PA, Ravenel J. Superior vena cava syndrome related to indwelling intravenous catheters in patients with cystic fibrosis. Pediatr Pulmonol 2006; 41: 683-7.
445
Smith D, Reid D, Slaughter R, et al. Superior vena cava obstruction due to total implantable venous access devices in cystic fibrosis: case series and review. Respir Med CME 2011; 4: 99-104.
446
Smith D, Reid D, Slaughter R, et al. Superior vena cava obstruction due to total implantable venous access devices in cystic fibrosis: case series and review. Respir Med CME 2011; 4: 99-104.
447
Balfour-Lynn IM, Malbon K, Burman JF et al. Thrombophilia in children with cystic fibrosis. Pediatr Pulmonol 2005; 39: 306-10.
448
Barker M, Thoenes D, Dohmen H, et al. Prevalence of thrombophilia and catheter-related thrombosis in cystic fibrosis. Pediatr Pulmonol 2005; 39: 156-61.
449
Williams V, Griffiths AB, Yap ZL, et al. Increased thrombophilic tendency in pediatric cystic fibrosis patients. Clin Appl Thromb Hemost2010; 16:71-6.
450
Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci 1998; 20: 149-60.
451
JuskoWJ,MosvichLL, Gerbracht LM, et al. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics 1974; 56: 1038-44.
452
Turvey S, Cronin B, Arnold A, et al. Dioun A. Antibiotic desensitization for the allergic patient: 5 years of experience and practice.
453
Peckham D, Whitaker P. Drug induced complications; can we do more? J Cyst Fibros 2013; 12: 547-58.
454
Hoffmann IM, Rubin BK, Iskandar SS, et al. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002; 34: 375-7.
455
Al-Aloul M, Miller H, Stockton P, et al. Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES). J Cyst Fibros 2005; 4:197–201.
456
Al-Aloul M, Miller H, Alapati S, et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39: 15–20.
457
Al-Aloul M, Miller H, Stockton P, et al. Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES). J Cyst Fibros 2005; 4:197–201.
458
Coifu O, Giwercman B, Pederssen SS, et al. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish Cystic Fibrosis Centre. Acta Pathol Microbiol Immunol Scand 1994; 102:674-80.
459
Breen L, Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 2012; 7: CD002767.
460
Elborn JS, Prescott R, Stack B, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection of the lungs. Thorax 2000; 55: 355-8.
461
Edson RS, Terrell CL The aminoglycosides. Mayo Clin Proc 1999; 74: 519-28.
462
Prayle A, Watson A, Fortnum H, et al. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax 2010:65:654-6.
463
Adeboyeku D, Jones AL, HodsonME. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. J Cyst Fibros 2011; 10:25–30.
464
Smyth A, Tan KH, Hyman-Taylor P et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis – the TOPIC study: a randomised controlled trial. Lancet 2005; 365: 573-8.
465
Mirakhur A, Gallagher MJ, Ledson MJ, et al. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros 2003; 2: 19–24.
466
Al-Aloul M, Ledson M, Walshaw MJ. Renoprotective effect of fosfomycin in the treatment of multiresistant Pseudomonas aeruginosa in CF. Thorax 2004; 59: 334-6.
467
Edson RS, Brey RH, McDonald TJ, et al. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc 2004; 79: 1185-91.
468
Ramsey BW, Pepe MS, QuanJM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23–30.
469
Mulheran M, Degg C, Burr S, et al. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated highdose aminoglycoside therapy. Antimicrob Agents Chemother 2001; 45: 2502-9.
470
Hennig S, McKay K, Vidmar S, et al. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis. J Cyst Fibros 2014; 13: 428-34.
471
Conrad DJ, Stenbit AE, Zettner EM, et al. Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population. Pharmacogenet Genomics 2008; 18: 1095-102.
472
Price DJE, Graham Dl. Effects of large doses of colistin sulphomethate on renal function. Br Med J 1970; 4: 525-7.
473
Koch-wester J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-68.
474
Ledson MJ, Gallagher MJ, Cowperthwaite C, et al. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 1998; 12: 592-4.
475
Ramsey BW, Pepe MS, QuanJM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23–30.
476
Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros 2014; 13Suppl 1:S23-42.
477
Al-Aloul M, Nazareth D, Walshaw M. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations. J Aerosol Med Pulm Drug Deliv 2014; 27: 299–305.
478
Harrison MJ, McCarthy M, Fleming C, et al. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J Cyst Fibros 2014; 13: 692-8.
479
Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis. Cochrane Database Syst Rev 2000; 2: CD000407
480
Scheuing N, Holl RW, Dockter G, et al. Diabetes in cystic fibrosis: multicenter screening results based on current guidelines. PloSOne2013;8:e81545.
481
Haworth CS. Impact of cystic fibrosis on bone health. Curr Opin Pulm Med 2010; 16: 616-22.
482
Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros 2014; 13Suppl 1:S23-42.
483
Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-69.
484
Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic
485
Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-69.
486
Lands LC, Stanojevic S. Oral nonsteroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database System Rev 2013; 6: CD001505.
487
Southern KW, Barker PM, Solis-Moya A, et al. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012;11:CD002203.
488
Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010; 303: 1707-15.
489
Hansen CR, Pressler T, Koch C, et al. Long-term azithromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 2005;4:35–40.
490
McKenzie SG, Chowdhury S, Strandvik B, et al. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. Pediatr Pulmonol 2007; 42: 928-37.
491
Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-40.
492
Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012; 185: 645-52.
493
Colombo JL. Long-acting bronchodilators in cystic fibrosis. Curr Opin Pulm Med 2003; 9: 504-8.
494
Bradley JM, Koker P, Deng Q, et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One 2014; 9: e106195.
495
FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997; 336: 1283-9.
496
Sinaasappel M, Stern M, Littlewood J, et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 2002; 1: 51–75.
497
Houwen RH, van der Doef HR Sermet I, et al. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr 2010; 50: 38–42.
498
McKone EF Borowitz D, Drevinek R et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med 2014; 2: 902-10.
499
NickJA, Moskowitz SM, Chmiel JF et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc 2014; 11: 342-50.
500
Skov M, Main KM, Sillesen IB, et al. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002; 20: 127-33.
501
Gilchrist FJ, Cox KJ, Rowe R, et al. Itraconazole and inhaled fluticasone causing hypothalamic-pituitary-adrenal axis suppression
502
CholonDM,QuinneyNL, Fulcher ML, et al. Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR'm cystic fibrosis. Sci Transl Med 2014; 6: 246ra96.
503
Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Sci Transl Med 2014; 6: 246ra97.
504
Robinson WM, RavillyS, Berde С, et al. End of life care in patients with cystic fibrosis. Pediatrics 1997; 100:205-9.
505
Robinson WM. Palliative care and end of life care in cystic fibrosis: what we know and what we need to know. Curr Opin Pulm Med 2009; 15:621-5.
506
Sands D, Repetto T, Dupont LJ, et al. End of life care for patients with cystic fibrosis. J Cyst Fibros 2011; 10(Suppl2):S37-S44.
507
Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352: 1992–2001.
508
Smyth AR, Bell SC, Bojcin S,et al. European Cystic Fibrosis Society Standards of care: Best practice guidelines. J Cyst Fibros 2014; 13 Suppl 1:S23-42.
509
Knoop C, Dupont LJ. Cystic fibrosis. In: Fisher AJ, Verleden GM, Massard G, eds. Lung transplantation. Eur Respir Monogr; 2009; 45:32–45.
510
Corris PA. Lung transplantation for cystic fibrosis and bronchiectasis. Semin Respir Crit Care Med 2013; 34: 297–304.
511
Mitchell I, Nakielna E, Tullis E, et al. Cystic fibrosis. End stage care in Canada. Chest 2000; 118:80-4.
512
Sood N, Paradowski LJ, Yankaskas JR. Outcomes of intensive unit care in adults with cystic fibrosis. Am J Respir Crit Care Med 2001; 163:335-8.
513
Bourke SJ, Doe SJ, Gascoigne AD, et al. An integrated model of provision of palliative care to patients with cystic fibrosis. Palliat Med 2009; 23: 512-7.
514
Jackson AD, Daly L, Kelleher C, et al. The application of current lifetable methods to compare cystic fibrosis median survival internationally is limited. J Cyst Fibros 2011; 10:62-5.
515
Hayes M, Yaster M, Haythornthwaite J, et al. Pain is a common problem affecting clinical outcomes in adults with cystic fibrosis. Chest 2011; 140: 1598-603.
516
Sawicki GS, Dill EJ, Asher D, et al. Advance care planning in adults with cystic fibrosis. J Palliat Med 2008; 11: 1135-41.
517
Braithwaite M, Philip J, Tranberg H, et al. End of life care in CF: patients, families and staff experiences and unmet needs. J Cyst Fibros 2011; 10:253-7.
518
Chapman AL. End of life care for adult CF patients – facilitating a good enough death. J Cyst Fibros 2005; 4: 249-57.
519
Braithwaite M, Philip J, Tranberg H, et al. End of life care in CF: patients, families and staff experiences and unmet needs. J Cyst Fibros 2011; 10:253-7.
520
Robinson W. Palliative care in cystic fibrosis. J Palliat Med 2000; 3: 187-92.
521
Stenekes SJ, Hughes A, Gregoire MC, et al. Frequency and selfmanagement of pain, dyspnea, and cough in cystic fibrosis. J Pain Symptom Manage 2009; 38: 837-48.
522
World Health Organization. WHO definition of palliative care, http://www.who.int/cancer/palliative/definition/en/ – 5 March 2014.
523
Chapman AL. End of life care for adult CF patients – facilitating a good enough death. J Cyst Fibros 2005; 4: 249-57.
524
Clisby N, Shaw S, Cormack M. Psychological impact of working with patients with cystic fibrosis at end-of-life, pre-transplant stage. Palliat Support Care 2013; 11:111-21.
525
Clisby N, Shaw S, Cormack M. Psychological impact of working with patients with cystic fibrosis at end-of-life, pre-transplant stage. Palliat Support Care 2013; 11:111-21.
526
Stenekes SJ, Hughes A, Gregoire MC, et al. Frequency and selfmanagement of pain, dyspnea, and cough in cystic fibrosis. J Pain Symptom Manage 2009; 38: 837-48.
527
Jennings AL, Davies AN, Higgins JPT, et al. A systematic review of use of opioids in the management of dyspnoea. Thorax 2002; 57: 939-44.
528
SchwartzsteinRM,LahiveK, Pope A, et al. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis1987; 136:58–61.
529
Kallet RH. The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care 2007; 52: 900-10.
530
Heslop K. Cognitive behavioural therapy in cystic fibrosis. J Royal Soc Med 2006; 99 (Suppl 46): 27-9.
531
Abernethy AP, McDonald CF, Firth PA, et al. Effects of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blinded randomised controlled trial. Lancet 2010; 376: 784-93.
532
Morice AH, Menon MS, Mulrennan SA, et al. Opiate therapy for chronic cough. Am J Respir Crit Care Med 2007; 175: 312-15.
533
Wee B, Browning J, Adams A, et al. Management of chronic cough in patients receiving palliative care: review of evidence and recommendations by a task group of the Association for Palliative Medicine of Great Britain and Ireland. Palliat Med 2012; 26: 780-7.
534
Sleeman KE, Collis E. Caring for a dying patient in hospital. BMJ 2013; 346: 33-7.
535
Ford D, Flume PA. Impact of lung transplantation on site of death in cystic fibrosis. J Cyst Fibros 2007; 6: 391-5.
536
Dellon EP, Leigh MW, Yankaskas JR, et al. Effects of lung transplantation on inpatient end of life care in cystic fibrosis. J Cyst Fibros 2007; 6: 396–402.
537
Hayes D Jr, Корр ВТ, Preston TJ et al. Survival of patients with cystic fibrosis on ECMO: analysis of the Extracorporeal Life Support Organization Registry. Int J Clin Exp Med 2014; 7: 1370-2.
538
Texereau J, Jamal D, Choukroun G et al. Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter study. Respir Res 2006;7:14–24.
539
Fauroux B, Burgel PR, Boelle PY, et al. Practice of noninvasive ventilation for cystic fibrosis: a nationwide survey in France. Respir Care 2008; 53: 1482-9.
540
Efrati 0, Modan-Moses D, Barak A, et al. Long-term non-invasive positive pressure ventilation among cystic fibrosis patients awaiting lung transplantation. Isr Med Assoc J 2004; 6: 527-30.
541
VedamH, MoriartyC, TorzilloPJ, et al. Improved outcomes of patient with cystic fibrosis admitted to the intensive care unit. J Cyst Fibros 2004; 3:8-14.
542
Bartz RR, Love RB, Leverson G, et al. Pre-transplant mechanical ventilation and outcome in patients with cystic fibrosis. J Heart Lung Transplant 2003; 22: 433-8.
543
Elizur A, Sweet SC, Huddleston CB, et al. Pre-transplant mechanical ventilation increases shortterm morbidity and mortality in pediatric patient with cystic fibrosis. J Heart Lung Transplant 2007; 26: 127-31.
544
Perilongo G, Rigon L, Sainati L. Palliative and terminal care for dying children. Proposal for better care. Med Ped Oncol 2001; 37: 59–61.
545
Collett L, Lester D. The fear of death and the fear of dying. J Psychol 1969; 72: 179-81.
546
Besier T, Schmitz TG, Goldbeck L. Life satisfaction of adolescents and adults with cystic fibrosis: impact of partnership and gender. J Cyst Fibros 2009; 8: 104-9.
547
Badlan K. Young people living with cystic fibrosis: an insight into their subjective experience. Health Soc Care Community 2006; 14: 264-70.
548
Walters S, Britton J, Hodson ME. Demographic and social characteristics of adults with cystic fibrosis in the United Kingdom. BMJ 1993;306:549-52.
549
TargettK, BourkeS, Nash E, etal. Employment in adults with cystic fibrosis. Occup Med (Lond) 2014;64:87–94.
550
Gillen M, Lallas D, Brown C, et al. Work disability in adults with cystic fibrosis. Am J Respir Crit Care Med 1995; 152: 153-6.
551
Laborde-Casterot H, Donnay C, Chapron J, et al. Employment and work disability in adults with cystic fibrosis. J Cyst Fibros 2012; 11: 137-43.
552
Paris W, Diercks M, Bright J, et al. Return to work after lung transplantation. J Heart Lung Transplant 1998; 17: 430-6.
553
CicuttoL, BraidyC, Moloney S, et al. Factors affecting attainment of paid employment after lung transplantation. J Heart Lung Transplant 2004; 23: 481-6.
554
Burker EJ, Sedway J, Carone S, et al. Vocational attainment of adults with CF: success in the face of adversity. J Rehabil 2005, 71:22-7.
555
Burker EJ, Sedway J, Carone S, et al. Vocational attainment of adults with CF: success in the face of adversity. J Rehabil 2005, 71:22-7.
556
Frangolias DD, Holloway CL, Vedal S, et al. Role of exercise and lung function in predicting work status in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 150-7.
557
Taylor-Robinson DC, Smyth R, Diggle PJ, et al. A longitudinal study of the impact of social deprivation and disease severity on employment status in the UK cystic fibrosis population. PloS One 2013; 8:e73322.
558
Taylor-Robinson DC, Smyth R, Diggle PJ, et al. A longitudinal study of the impact of social deprivation and disease severity on employment status in the UK cystic fibrosis population. PloS One 2013; 8:e73322.
559
Hogg M, Braithwaite M, Bailey M, et al. Work disability in adults with cystic fibrosis and its relationship to quality of life. J Cyst Fibros 2007; 6: 223-7.
560
TargettK, BourkeS, Nash E, etal. Employment in adults with cystic fibrosis. Occup Med (Lond) 2014;64:87–94.
561
Burker EJ, Sedway J, Carone S. Psychological and educational factors: better predictors of work status than FEV, in adults with cystic fibrosis. Pediatr Pulmonol 2004;38:413-18.
562
Taylor-Robinson DC, Smyth R, Diggle PJ, et al. A longitudinal study of the impact of social deprivation and disease severity on employment status in the UK cystic fibrosis population. PloS One 2013; 8:e73322.
563
Laborde-Casterot H, Donnay C, Chapron J, et al. Employment and work disability in adults with cystic fibrosis. J Cyst Fibros 2012; 11: 137-43.
564
Demars N, Uluer A, Sawicki GS. Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil 2011; 33: 922-6.